Hired and retired: New appointments in the biopharma industry

Florence BuchananDecember 2, 2022CDMO, UK CDMO, ViroCell, gene therapy, cell and gene therapies, cell therapy, viral vector, viral vectors, New hires, Nick Maishman

Gene therapy ‘factory’ to save children

A new “factory” that will produce benign viruses for Great Ormond Street Hospital is expected to accelerate the development of life-saving gene therapy drugs.

The facility, which is based in the hospital and operated by the biotech company ViroCell Biologics, will more than double Britain’s capacity to manufacture a key type of gene therapy.

ViroCell Announces new Board appointments

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of J. David Enloe, Jr. to its Board of Directors and Martin Pule, MD, PhD to its Scientific Advisory Board, both leaders in their respective fields.

Tech News: ViroCell Biologics

ViroCell Biologics, the UK’s first clinical trial-focused viral vector manufacturer, has officially launched.

It aims to be the supplier of choice for viral vectors and gene-modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

In the NewsFlorence BuchananJune 3, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, The Biomedical Scientist, vector design, gene therapy, cell therapy, CGT, UK CDMO, Farzin Farzaneh, King's College London, viral vector

ViroCell released in the UK to make viral vectors

ViroCell will supply viral vectors and genetically modified cells to academic and corporate customers for translational cell and gene therapy entering clinical trials.

Global Roundup. Elsewhere across the globe: ViroCell Biologics

ViroCell Biologics – U.K.-based ViroCell launched with the goal to become the supplier of choice for viral vectors and gene-modified cells. Viral vectors are the primary delivery method for many innovative vaccines.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, BioSpace, UK CDMO, ViroCell, gene therapy, cell therapy, viral vector, vector design, AAV vectors, lentivirus vectors, Farzin Farzaneh

Introducing ViroCell Biologics. The UK’s first clinical trial focused viral vector manufacturer.

ViroCell Biologics, founded in the UK by a prolific academic viral vector manufacturing team, has officially launched. Viral vectors are the primary delivery method for innovative vaccines such as the Oxford/Astra Zeneca COVID vaccine, as well as enabling inputs for the manufacture of the rapidly growing Cell and Gene Therapy sector (CGT).

In the NewsFlorence BuchananApril 28, 2021CDMO, ViroCell, viral vector, viral vectors, AAV vectors, lentivirus vectors, gene therapy, cell therapy, CGT, Farzin Farzaneh, John W. Hadden II, Contract Pharma, UK CDMO, vector design

First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the first clinical trial focused viral vector manufacturer in the UK, has announced its official launch, with the aim of becoming the ‘supplier of choice’ for viral vectors and gene modified cells.

In the NewsFlorence BuchananApril 28, 2021CDMO, ViroCell, Truell Conservation Foundation, Farzin Farzaneh, John Hadden II, gene therapy, cell therapy, CGT, viral vector, viral vectors, vector design, AAV vectors, lentivirus vectors, UK CDMO, PharmaJobs

Edi Truell leads financing of gene therapy start-up ViroCell Biologics

Edi Truell is backing a gene and cell therapy start-up and is seeking to lead a £100 million financing as part of his latest venture.

In the NewsFlorence BuchananApril 12, 2021Edi Truell, gene therapy, cell therapy, CDMO, UK CDMO, viral vector, viral vectors, AAV vectors, lentivirus vectors, ViroCell, The Times, Farzin Farzaneh, John W. Hadden II, Truell Conservaton Foundation, Danny Truell, Syncona

In the news

London New York